ClinicalTrials.gov
public full text
Public Domain
Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs#1112109
- Rosiglitazone on Microalbuminuria in Type 2 Diabetics#674874
- Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes#854436
- Glitazones and Endothelial Function (GATE)#1032976
- Study of Rivoglitazone in Type 2 Diabetes Mellitus#858190
Record · ID 884778
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive